New Index for Medication-Related Anticholinergic Exposure and Cognitive Impairment Risk
Author Information
Author(s): Michaud Veronique, Autar Kaveena, Condon Gerald, Honore Chelsea, Grisales Maria, Hickman James, Turgeon Jacques
Primary Institution: GalenusRx Inc
Hypothesis
Can a new cumulative anticholinergic exposure index better evaluate the risk of cognitive impairment in older adults?
Conclusion
The study developed a new index that quantifies anticholinergic exposure and its impact on cognitive impairment risk in older adults.
Supporting Evidence
- The study compiled a comprehensive list of 642 drugs with anticholinergic activities.
- A new Medication-Related Cumulative Anticholinergic Exposure index was developed.
- The analysis showed significant shifts in MeReCAE values with certain medications.
Takeaway
This study created a new way to measure how certain medications can affect the brain, especially in older people.
Methodology
The study used human-on-a-chip technology and analyzed drug regimen data from the Medical Expenditure Panel Survey.
Participant Demographics
Older adults, with data extracted from a large patient survey.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website